vs
Side-by-side financial comparison of FGI Industries Ltd. (FGI) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $30.5M, roughly 1.3× FGI Industries Ltd.). FGI Industries Ltd. runs the higher net margin — -8.6% vs -161.8%, a 153.2% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -14.4%). FGI Industries Ltd. produced more free cash flow last quarter ($2.3M vs $-71.3M).
FGI Industries Ltd is a global designer, manufacturer and distributor of kitchen and bath products, home organization solutions, and home improvement goods. It serves major retail chains, home specialty stores and e-commerce platforms across North America, Europe and the Asia-Pacific region.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
FGI vs IBRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.5M | $38.3M |
| Net Profit | $-2.6M | $-61.9M |
| Gross Margin | 26.7% | 99.0% |
| Operating Margin | -2.2% | -169.0% |
| Net Margin | -8.6% | -161.8% |
| Revenue YoY | -14.4% | 407.0% |
| Net Profit YoY | -553.1% | -4.7% |
| EPS (diluted) | $-1.63 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.5M | $38.3M | ||
| Q3 25 | $35.8M | $32.1M | ||
| Q2 25 | $31.0M | $26.4M | ||
| Q1 25 | $33.2M | $16.5M | ||
| Q4 24 | $35.6M | $7.6M | ||
| Q3 24 | $36.1M | $6.1M | ||
| Q2 24 | $29.4M | — | ||
| Q1 24 | $30.8M | — |
| Q4 25 | $-2.6M | $-61.9M | ||
| Q3 25 | $-1.7M | $-67.3M | ||
| Q2 25 | $-1.2M | $-92.6M | ||
| Q1 25 | $-629.1K | $-129.6M | ||
| Q4 24 | $-402.3K | $-59.2M | ||
| Q3 24 | $-550.1K | $-85.7M | ||
| Q2 24 | $163.6K | — | ||
| Q1 24 | $-412.2K | — |
| Q4 25 | 26.7% | 99.0% | ||
| Q3 25 | 26.5% | 99.4% | ||
| Q2 25 | 28.1% | 99.5% | ||
| Q1 25 | 26.8% | 99.6% | ||
| Q4 24 | 24.6% | — | ||
| Q3 24 | 25.8% | — | ||
| Q2 24 | 30.5% | — | ||
| Q1 24 | 27.4% | — |
| Q4 25 | -2.2% | -169.0% | ||
| Q3 25 | 1.0% | -173.5% | ||
| Q2 25 | -2.7% | -269.8% | ||
| Q1 25 | -3.9% | -390.1% | ||
| Q4 24 | -3.5% | -919.0% | ||
| Q3 24 | -0.2% | -1314.3% | ||
| Q2 24 | -1.5% | — | ||
| Q1 24 | -1.0% | — |
| Q4 25 | -8.6% | -161.8% | ||
| Q3 25 | -4.6% | -209.8% | ||
| Q2 25 | -4.0% | -350.3% | ||
| Q1 25 | -1.9% | -784.9% | ||
| Q4 24 | -1.1% | -783.4% | ||
| Q3 24 | -1.5% | -1404.0% | ||
| Q2 24 | 0.6% | — | ||
| Q1 24 | -1.3% | — |
| Q4 25 | $-1.63 | $-0.06 | ||
| Q3 25 | $-0.86 | $-0.07 | ||
| Q2 25 | $-0.64 | $-0.10 | ||
| Q1 25 | $-0.07 | $-0.15 | ||
| Q4 24 | $-0.38 | $-0.08 | ||
| Q3 24 | $-0.29 | $-0.14 | ||
| Q2 24 | $0.08 | — | ||
| Q1 24 | $-0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9M | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $17.3M | $-500.5M |
| Total Assets | $69.5M | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.9M | $242.8M | ||
| Q3 25 | $1.9M | $257.8M | ||
| Q2 25 | $2.5M | $153.7M | ||
| Q1 25 | $1.2M | $61.6M | ||
| Q4 24 | $4.6M | $149.8M | ||
| Q3 24 | $3.0M | $130.4M | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $3.3M | — |
| Q4 25 | $17.3M | $-500.5M | ||
| Q3 25 | $19.7M | $-524.3M | ||
| Q2 25 | $21.3M | $-570.7M | ||
| Q1 25 | $21.8M | $-591.4M | ||
| Q4 24 | $22.3M | $-489.1M | ||
| Q3 24 | $23.5M | $-745.1M | ||
| Q2 24 | $23.8M | — | ||
| Q1 24 | $23.9M | — |
| Q4 25 | $69.5M | $501.9M | ||
| Q3 25 | $73.0M | $519.0M | ||
| Q2 25 | $71.7M | $402.1M | ||
| Q1 25 | $68.5M | $303.8M | ||
| Q4 24 | $75.5M | $382.9M | ||
| Q3 24 | $74.7M | $364.6M | ||
| Q2 24 | $69.9M | — | ||
| Q1 24 | $68.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.3M | $-70.4M |
| Free Cash FlowOCF − Capex | $2.3M | $-71.3M |
| FCF MarginFCF / Revenue | 7.5% | -186.2% |
| Capex IntensityCapex / Revenue | 0.2% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-212.5K | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.3M | $-70.4M | ||
| Q3 25 | $-1.9M | $-68.9M | ||
| Q2 25 | $7.6M | $-79.7M | ||
| Q1 25 | $-7.4M | $-85.9M | ||
| Q4 24 | $617.4K | $-85.1M | ||
| Q3 24 | $-915.0K | $-98.8M | ||
| Q2 24 | $862.1K | — | ||
| Q1 24 | $-8.0M | — |
| Q4 25 | $2.3M | $-71.3M | ||
| Q3 25 | $-2.1M | $-69.6M | ||
| Q2 25 | $7.4M | $-80.8M | ||
| Q1 25 | $-7.7M | $-87.0M | ||
| Q4 24 | $-214.1K | $-87.3M | ||
| Q3 24 | $-1.1M | $-101.6M | ||
| Q2 24 | $281.5K | — | ||
| Q1 24 | $-8.6M | — |
| Q4 25 | 7.5% | -186.2% | ||
| Q3 25 | -5.9% | -217.2% | ||
| Q2 25 | 23.8% | -305.9% | ||
| Q1 25 | -23.3% | -526.9% | ||
| Q4 24 | -0.6% | -1155.4% | ||
| Q3 24 | -3.0% | -1663.2% | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | -28.0% | — |
| Q4 25 | 0.2% | 2.4% | ||
| Q3 25 | 0.7% | 2.3% | ||
| Q2 25 | 0.7% | 4.1% | ||
| Q1 25 | 1.1% | 6.8% | ||
| Q4 24 | 2.3% | 28.0% | ||
| Q3 24 | 0.5% | 45.7% | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 2.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.27× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FGI
| Sanitaryware | $19.1M | 63% |
| Shower System | $5.8M | 19% |
| Kitchen And Bath Other | $3.3M | 11% |
| Bath Furniture Products | $2.3M | 7% |
IBRX
Segment breakdown not available.
